checkAd

Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Tuesday, November 15, 2022 at 5:00 p.m. (EST) to discuss corporate developments and financial results for the third quarter ended September 30, 2022.

Dr. Michael Rosol, Chief Medical Officer, and Erika Eves, Vice President of Finance and Administration, will host the call and webcast to discuss the financial results and provide an update on recent developments and clinical progress. Management will be available to answer questions live immediately following the earnings announcement and prepared remarks portion of the call.

To participate in the call and webcast, please refer to the information below:

Event:

 

Third Quarter 2022 Earnings Conference Call and Business Update

Date:

 

Tuesday, November 15, 2022

Time:

 

5:00 p.m. (EST)

U.S. & Canada Dial-In:

 

877-407-0312

International Dial-In:

 

+1 201-389-0899

Conference ID:

 

13733801

Webcast Link:

 

https://www.webcast-eqs.com/navidbioph20221115/en

A live audio webcast of the conference call will also be available on the investor relations page of Navidea’s corporate website at www.navidea.com. In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Navidea’s website.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Seite 1 von 2




0 Kommentare
Nachrichtenquelle: Business Wire (engl.)
 |  101   |   |   

Schreibe Deinen Kommentar

Disclaimer

Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on …

Nachrichten des Autors

232 Leser
224 Leser
220 Leser
204 Leser
204 Leser
176 Leser
160 Leser
160 Leser
156 Leser
156 Leser
1696 Leser
768 Leser
564 Leser
544 Leser
452 Leser
444 Leser
432 Leser
404 Leser
396 Leser
368 Leser
3236 Leser
2100 Leser
1928 Leser
1696 Leser
1604 Leser
1344 Leser
1168 Leser
1164 Leser
1116 Leser
1080 Leser
7528 Leser
3236 Leser
3061 Leser
2934 Leser
2497 Leser
2416 Leser
2370 Leser
2169 Leser
2106 Leser
2100 Leser